Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies
Recombinant therapeutic proteins, of which monoclonal antibodies (mAbs) represent the largest market, are used to treat diseases including cancer, blood and immune disorders. The cost and complexity of large-scale production and purification of mAbs translates to high cost of therapy. We hypothesise...
| Principais autores: | , , , , |
|---|---|
| Formato: | Conference item |
| Publicado em: |
Mary Ann Liebert Inc
2016
|
| _version_ | 1826276474908311552 |
|---|---|
| author | Antepowicz, A Tan, A Pringle, A Hyde, S Gill, D |
| author_facet | Antepowicz, A Tan, A Pringle, A Hyde, S Gill, D |
| author_sort | Antepowicz, A |
| collection | OXFORD |
| description | Recombinant therapeutic proteins, of which monoclonal antibodies (mAbs) represent the largest market, are used to treat diseases including cancer, blood and immune disorders. The cost and complexity of large-scale production and purification of mAbs translates to high cost of therapy. We hypothesise that our rSIV.F/HN lentiviral lung gene delivery platform, currently undergoing preclinical evaluation for cystic fibrosis gene therapy, could be used to establish protein factories within patients' lungs. |
| first_indexed | 2024-03-06T23:14:30Z |
| format | Conference item |
| id | oxford-uuid:66a643d1-7c76-4447-a7b5-8311b6e93d03 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T23:14:30Z |
| publishDate | 2016 |
| publisher | Mary Ann Liebert Inc |
| record_format | dspace |
| spelling | oxford-uuid:66a643d1-7c76-4447-a7b5-8311b6e93d032022-03-26T18:33:26ZDevelopment of lung and muscle protein factories to deliver therapeutic monoclonal antibodiesConference itemhttp://purl.org/coar/resource_type/c_5794uuid:66a643d1-7c76-4447-a7b5-8311b6e93d03Symplectic Elements at OxfordMary Ann Liebert Inc2016Antepowicz, ATan, APringle, AHyde, SGill, DRecombinant therapeutic proteins, of which monoclonal antibodies (mAbs) represent the largest market, are used to treat diseases including cancer, blood and immune disorders. The cost and complexity of large-scale production and purification of mAbs translates to high cost of therapy. We hypothesise that our rSIV.F/HN lentiviral lung gene delivery platform, currently undergoing preclinical evaluation for cystic fibrosis gene therapy, could be used to establish protein factories within patients' lungs. |
| spellingShingle | Antepowicz, A Tan, A Pringle, A Hyde, S Gill, D Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies |
| title | Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies |
| title_full | Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies |
| title_fullStr | Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies |
| title_full_unstemmed | Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies |
| title_short | Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies |
| title_sort | development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies |
| work_keys_str_mv | AT antepowicza developmentoflungandmuscleproteinfactoriestodelivertherapeuticmonoclonalantibodies AT tana developmentoflungandmuscleproteinfactoriestodelivertherapeuticmonoclonalantibodies AT pringlea developmentoflungandmuscleproteinfactoriestodelivertherapeuticmonoclonalantibodies AT hydes developmentoflungandmuscleproteinfactoriestodelivertherapeuticmonoclonalantibodies AT gilld developmentoflungandmuscleproteinfactoriestodelivertherapeuticmonoclonalantibodies |